CAMBRIDGE, Mass.--(BUSINESS WIRE)--Pandion Therapeutics, a biotechnology company developing novel targeted therapeutics to treat autoimmune and inflammatory diseases and transplant rejection, today announced the formation of its Scientific Advisory Board (SAB). The inaugural members include Diane Mathis, PhD, Scott Snapper, MD, PhD, Ananda Goldrath, PhD and David H. Sachs, MD.
“Our founding SAB members are world-renowned scientists with impressive track records in academic and translational research, and we are thrilled that they will be working closely with our science team as we advance our lead molecules toward the clinic,” said Jo Viney, PhD, co-founder and CSO of Pandion Therapeutics.
Diane Mathis, PhD, is a professor in the Department of Microbiology and Immunobiology at Harvard Medical School and holder of the Morton Grove-Rasmussen Chair in Immunohematology. She is also a Principal Faculty Member at the Harvard Stem Cell Institute and an Associate Faculty Member of the Broad Institute. Her research focuses on T cell differentiation, autoimmunity, and inflammation. She is a member of the National Academy of Sciences, the American Academy of Arts and Sciences, and the German Academy.
Scott Snapper, MD, PhD, is the Wolpow Family Chair and Director of the Center for Inflammatory Bowel Disease and Director of Basic and Translational Research at Boston Children’s Hospital. He is also Director of IBD Research in the Gastroenterology division at Brigham and Women’s Hospital and is Professor of Medicine at Harvard Medical School. His laboratory is focused on discovering new genetic associations in IBD and testing novel strategies to treat disease. Dr. Snapper is the chair of the National Scientific Advisory Board of the Crohn’s & Colitis Foundation.
Ananda Goldrath, PhD, is a Professor and Chair of the Molecular Biology Section in the Division of Biology at the University of California, San Diego. Her work has advanced the understanding of transcriptional regulation of T cell activation, differentiation, and homeostasis. Her research is currently focused on investigating new ways to induce the immune system to provide protection from infections and eradicate malignancy. Dr. Goldrath is a Pew Scholar and a Leukemia and Lymphoma Society Fellow.
David H. Sachs, MD, a co-founder of Pandion, is Professor Emeritus of Surgery at Harvard Medical School and Professor of Surgery at Columbia University Medical Center. His research focuses on several aspects of transplantation, including induction of transplant tolerance. He is a member of the National Academy of Medicine of the National Academy of Sciences.
“We are honored to have Dr. Mathis, Dr. Snapper and Dr. Goldrath partner with us and to strengthen our relationship with Dr. Sachs. We believe their insight and contributions to our science will be invaluable as we build the next generation of therapeutics with transformative potential,” said Anthony Coyle, PhD, co-founder and CEO of Pandion Therapeutics.
About Pandion Therapeutics
Pandion Therapeutics is developing a pipeline of antibody therapeutics to achieve localized immunomodulation for autoimmune and inflammatory diseases and transplantation. The company’s proprietary technology platform enables the design of bispecific antibodies with targeting fragments that bind to specific tissues at the local site of inflammatory disease, coupled with effector molecules that modulate immune activity to restore immune homeostasis.
Pandion was founded in 2017 and closed a $58M Series A financing round in early 2018 with funding from Polaris Partners, Versant Ventures, Roche Venture Fund, SR One, and BioInnovation Capital. The company is headquartered in Cambridge, Massachusetts. Please visit www.pandiontx.com.
